Matthew J. Boron, RPh joined the Cancer Therapy Evaluation Program (CTEP) in 2000 as a Clinical Research Pharmacist in the Drug Management and Authorization Section (DMAS) of the Pharmaceutical Management Branch (PMB), where he was responsible for a portfolio of biologic agents under CTEP Investigational New Drug applications (INDs). In 2002, he transitioned to management of the Treatment Referral Center (TRC). The TRC provides referrals to clinical trials and mechanisms for access to NCI IND agents when conventional therapy and clinical trial therapies are no longer an option. Most commonly referred to as compassionate use, the available mechanisms through the TRC for treatment outside of clinical trials are Special Exceptions, Group C protocols, and TRC protocols. In addition to managing the TRC, he currently is also responsible for management of a number of blinded trials conducted through CTEP.
Mr. Boron earned his Bachelors of Science degree in Pharmacy from Duquesne University in 1993. He has held previous positions as a pharmacist at Mercy Hospital in Pittsburgh, as well as oncology pharmacist positions at MetroHealth Medical Center, University Hospitals Case Medical Center, and the Ireland Cancer Center in Cleveland Ohio. His responsibilities included inpatient pharmacy, IV room, as well as both inpatient and outpatient oncology units. He also spent time working for a large pharmaceutical company handling drug information questions.